Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Matthay

Showing results (271-280 of 316) with videos related to

Pageof 32
Sort By:
Cancer|July 12, 2017
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupKevin Campbell, Julie M Gastier-Foster, Meegan Mann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 6, 2016
Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology GroupWilliam Temple, Lori Mendelsohn, Grace E Kim, et al.
Pediatric Blood & Cancer|January 27, 2022
Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countriesKatherine K Matthay, Jennifer Hylton, Neela Penumarthy, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupKaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Cancer|July 15, 1997
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer GroupJ D Frost, J A Hank, G H Reaman, et al.
Medical Physics|October 23, 2010
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PETChang-Lae Lee, Hilla Wahnishe, George A Sayre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641Douglas R Strother, Wendy B London, Mary Lou Schmidt, et al.
International Journal of Molecular Imaging|October 11, 2012
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology GroupSteven G Dubois, Ethan Geier, Vandana Batra, et al.
Pageof 32

Showing results (271-280 of 316) with videos related to

Sort By:
Pageof 32
Cancer|July 12, 2017
Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupKevin Campbell, Julie M Gastier-Foster, Meegan Mann, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2010
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group ProjectVeronica Moroz, David Machin, Andreas Faldum, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 6, 2016
Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology GroupWilliam Temple, Lori Mendelsohn, Grace E Kim, et al.
Pediatric Blood & Cancer|January 27, 2022
Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countriesKatherine K Matthay, Jennifer Hylton, Neela Penumarthy, et al.
The New England Journal of Medicine|October 1, 2010
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaDavid L Baker, Mary L Schmidt, Susan L Cohn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupKaci L Osenga, Jacquelyn A Hank, Mark R Albertini, et al.
Cancer|July 15, 1997
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer GroupJ D Frost, J A Hank, G H Reaman, et al.
Medical Physics|October 23, 2010
Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PETChang-Lae Lee, Hilla Wahnishe, George A Sayre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641Douglas R Strother, Wendy B London, Mary Lou Schmidt, et al.
International Journal of Molecular Imaging|October 11, 2012
Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology GroupSteven G Dubois, Ethan Geier, Vandana Batra, et al.
Pageof 32